Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib Drug-Drug Interaction Study in AML
NCT03720366Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of enasidenib in acute myeloid leukemia (AML) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Curve from time 0 to 30 hours and Maximum Plasma Concentration at Day 28. Started Oct 2018; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03720366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720366.